Vertex Phase IIb Data On Telaprevir Support 24-Week Dosing For Hepatitis C
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vertex released positive interim data from Phase IIb studies of its experimental protease inhibitor telaprevir for the treatment of hepatitis C Nov. 2 at the American Association of the Study of Liver Diseases meeting in Boston